Code Bio was founded on the belief that more can be done for people living with debilitating genetic diseases. We are driven by the potential of our transformative technology to deliver precision genetic medicines for patients.
Code Bio leverages its proprietary, novel, multivalent, synthetic DNA delivery platform, 3DNA®, which has been engineered to overcome many of the challenges inherent with delivery of genetic medicines, such as: dose related toxicity, off-target effects, immunogenicity, gene size and delivery limitations, bioavailability, ability to re-dose, and vector manufacturing complexity.
The Company is advancing an internal pipeline focusing on a variety of diseases with its most advanced research in Duchenne’s Muscular Dystrophy (DMD). Code Bio also has research programs underway based on targeting data focused on the lungs, pancreas, and liver.
Company Details
- Employees
- 28
- Founded
- -
- Address
- 2801 Sterling Dr, Hatfield,pennsylvania 19440,united States
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- https://www.codebiotx.com/
- Keywords
- Manager jobs.
- HQ
- Hatfield, Pennsylvania
Code Biotherapeutics Questions
Code Biotherapeutics's website is https://www.codebiotx.com/
Code Biotherapeutics's LinkedIn profile is https://www.linkedin.com/company/code-biotherapeutics
Code Biotherapeutics has
28 employees.
View email and phone details for 28
employees at Code Biotherapeutics.
Code Biotherapeutics's industry is
Biotechnology Research
Code Biotherapeutics's top competitors are
Ptc Therapeutics, Inc.,
Swanbio Therapeutics,
Spark Therapeutics, Inc.,
Carisma Therapeutics,
Cabaletta Bio,
Iecure, Inc.,
Larimar Therapeutics Inc.,
Interius Biotherapeutics,
Genisphere,
Verismo Therapeutics.
Code Biotherapeutics's categories are Biotechnology Research
Code Biotherapeutics's founding year is 2020
